En vivo
Endpoints NewsLilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drugEndpoints NewsTrodelvy misses in lung cancer, but Gilead and Merck have an HIV successFierceBiotechADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal programFierceBiotechLilly moves deeper into Alzheimer’s research with AlzeCure licensing dealFierceBiotechCancer biotech Parabilis ups IPO plans to potentially record-setting $637MEndpoints NewsEndpoints Women in Biopharma: Nominate for 2026Lonza NewsAmMax Bio licenses ADC technology from Lonza - The Pharma LetterFDA News ReleasesFDA Expands Sunscreen Options for the First Time in 20 YearsEndpoints NewsPharma and biotech salaries: Top-paying companies of 2025FierceBiotechRoche sticks with €600M diagnostics investment in Germany but warns of future risk10x Genomics Blog10x Genomics (TXG) Expands Capabilities with Proteintech Genomics Acquisition - GuruFocusFierceBiotechCeQur nabs $100M series E to fuel insulin patch commercialization
BioWorld 5 dic 2025

New FGFR3 inhibitors disclosed in Onco3r Therapeutics patent

New FGFR3 inhibitors disclosed in Onco3r Therapeutics patent

Original
Contenido no disponible. Consulta la fuente original.